AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Abbvie (ABBV) PT Raised to $180 at Goldman Sachs
February 5, 2024 5:58 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $180.00 (from $173.00) while maintaining a Buy rating.
The analyst comments "4Q23 results and management's commentary on the FY24 and longer-term outlook strengthen our confidence in the potential for ABBV shares to continue to outperform. Across the company's Immunology... More
AbbVie (ABBV) tops Q4 earnings, revenue consensus estimate
February 2, 2024 8:37 AM ESTAbbVie (NYSE: ABBV) shares edged around 1% higher early Friday after the company reported earnings before the open, topping fourth-quarter profit and revenue expectations.
The American pharmaceutical company reported fourth-quarter adjusted earnings of $2.79 per share, $0.02 better than the analyst estimate of $2.77. Meanwhile, revenue... More
AbbVie (ABBV) Tops Q4 EPS by 2c, Beats on Revenue; Offers FY24 EPS Guidance
February 2, 2024 7:37 AM EST(Updated - February 2, 2024 7:40 AM EST)
AbbVie (NYSE: ABBV) reported Q4 EPS of $2.79, $0.02 better than the analyst estimate of $2.77. Revenue for the quarter came in at $14.3 billion versus the consensus estimate of $14.01 billion.
GUIDANCE:
AbbVie sees FY2024 EPS of... More
